Cargando…
Epigenetics in prostate cancer treatment
Prostate cancer (PCa) is the most commonly diagnosed malignancy among men, and the progression of this disease results in fewer treatment options available to clinical patients. It highlights the vital necessity for discovering novel therapeutic approaches and expanding the current understanding of...
Autores principales: | Jones, Katelyn, Zhang, Yanquan, Kong, Yifan, Farah, Elia, Wang, Ruixin, Li, Chaohao, Wang, Xinyi, Zhang, ZhuangZhuang, Wang, Jianlin, Mao, Fengyi, Liu, Xiaoqi, Liu, Jinghui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974353/ https://www.ncbi.nlm.nih.gov/pubmed/35372800 http://dx.doi.org/10.20517/jtgg.2021.19 |
Ejemplares similares
-
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer
por: Liu, Jinghui, et al.
Publicado: (2020) -
Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling
por: Li, Chaohao, et al.
Publicado: (2023) -
A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer
por: Liu, Jinghui, et al.
Publicado: (2023) -
Epigenetic regulation of prostate cancer
por: Wang, Ruixin, et al.
Publicado: (2019) -
Co‐Targeting Plk1 and DNMT3a in Advanced Prostate Cancer
por: Zhang, Zhuangzhuang, et al.
Publicado: (2022)